Lachey Jennifer's Form 4 filing
Keros Therapeutics, Inc. (KROS) · filed Jul 19, 2022
- Accession no.
- 0001209191-22-042573
- Filed
- Jul 19, 2022, 4:40 PM ET
- Trade date
- Jul 15, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.38M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lachey JenniferCIK 0001808322 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 15, 2022 | Common Stock | MOption exerciseAcquired | +46,034 | $0.30 | +$13,810.2 | 141,134 | Direct | |
| Jul 15, 2022 | Common Stock | SSaleDisposed | −46,034 | $30.00 | −$1,381,020 | 95,100 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 15, 2022 | Common Stock | MOption exerciseDisposed | −46,034 | $0.00 | $0 | 8,755 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.